Literature DB >> 28603224

Proton Beam Therapy for Pediatric Brain Tumor.

Masashi Mizumoto1, Yoshiko Oshiro1,2, Tetsuya Yamamoto3, Hidehiro Kohzuki3, Hideyuki Sakurai1.   

Abstract

Cancer is a major cause of childhood death, with central nervous system (CNS) neoplasms being the second most common pediatric malignancy, following hematological cancer. Treatment of pediatric CNS malignancies requires multimodal treatment using a combination of surgery, chemotherapy, and radiotherapy, and advances in these treatments have given favorable results and longer survival. However, treatment-related toxicities have also occurred, particularly for radiotherapy, after which secondary cancer, reduced function of irradiated organs, and retarded growth are significant problems. Proton beam therapy (PBT) is a particle radiotherapy with excellent dose localization that permits treatment of liver and lung cancer by administration of a high dose to the tumor while minimizing damage to surrounding normal tissues. Thus, PBT has the potential advantages for pediatric cancer. In this context, we review the current knowledge on PBT for treatment of pediatric CNS malignancies.

Entities:  

Keywords:  brain; children; pediatric; proton beam therapy; proton radiotherapy

Mesh:

Year:  2017        PMID: 28603224      PMCID: PMC5566707          DOI: 10.2176/nmc.ra.2017-0003

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  92 in total

1.  Report of Brain Tumor Registry of Japan (1984-2000).

Authors: 
Journal:  Neurol Med Chir (Tokyo)       Date:  2009       Impact factor: 1.742

2.  Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.

Authors:  Jacques Grill; Christian Sainte-Rose; Anne Jouvet; Jean-Claude Gentet; Odile Lejars; Didier Frappaz; François Doz; Xavier Rialland; Fabienne Pichon; Anne-Isabelle Bertozzi; Pascal Chastagner; Dominique Couanet; Jean-Louis Habrand; Marie-Anne Raquin; Marie-Cécile Le Deley; Chantal Kalifa
Journal:  Lancet Oncol       Date:  2005-08       Impact factor: 41.316

3.  Neuropsychological sequelae of the treatment of children with medulloblastoma.

Authors:  M Dennis; B J Spiegler; C R Hetherington; M L Greenberg
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

4.  Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study.

Authors:  Maura Massimino; Lorenza Gandola; Felice Giangaspero; Alessandro Sandri; Pinuccia Valagussa; Giorgio Perilongo; Maria Luisa Garrè; Umberto Ricardi; Marco Forni; Lorenzo Genitori; Giovanni Scarzello; Filippo Spreafico; Salvina Barra; Maurizio Mascarin; Bianca Pollo; Martina Gardiman; Armando Cama; Pierina Navarria; Maurizio Brisigotti; Paola Collini; Rita Balter; Paola Fidani; Maurizio Stefanelli; Roberta Burnelli; Paolo Potepan; Marta Podda; Guido Sotti; Enrico Madon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-04-01       Impact factor: 7.038

5.  Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma.

Authors:  W H St Clair; J A Adams; M Bues; B C Fullerton; Sean La Shell; H M Kooy; J S Loeffler; N J Tarbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

6.  Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function.

Authors:  Thomas E Merchant; Chia-Ho Hua; Hemant Shukla; Xiaofei Ying; Simeon Nill; Uwe Oelfke
Journal:  Pediatr Blood Cancer       Date:  2008-07       Impact factor: 3.167

7.  Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons.

Authors:  Shannon M MacDonald; Sairos Safai; Alexei Trofimov; John Wolfgang; Barbara Fullerton; Beow Y Yeap; Thomas Bortfeld; Nancy J Tarbell; Torunn Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-05       Impact factor: 7.038

8.  First experiences in treatment of low-grade glioma grade I and II with proton therapy.

Authors:  Henrik Hauswald; Stefan Rieken; Swantje Ecker; Kerstin A Kessel; Klaus Herfarth; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2012-11-09       Impact factor: 3.481

9.  Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy.

Authors:  Benjamin J Moeller; Murali Chintagumpala; Jimmy J Philip; David R Grosshans; Mary F McAleer; Shiao Y Woo; Paul W Gidley; Tribhawan S Vats; Anita Mahajan
Journal:  Radiat Oncol       Date:  2011-06-02       Impact factor: 3.481

10.  Long-term follow-up after proton beam therapy for pediatric tumors: a Japanese national survey.

Authors:  Masashi Mizumoto; Shigeyuki Murayama; Tetsuo Akimoto; Yusuke Demizu; Takashi Fukushima; Yuji Ishida; Yoshiko Oshiro; Haruko Numajiri; Hiroshi Fuji; Toshiyuki Okumura; Hiroki Shirato; Hideyuki Sakurai
Journal:  Cancer Sci       Date:  2017-03       Impact factor: 6.716

View more
  18 in total

Review 1.  Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.

Authors:  Simon Deycmar; Martin Pruschy
Journal:  Int J Part Ther       Date:  2018-09-21

Review 2.  The relative biological effectiveness of proton irradiation in dependence of DNA damage repair.

Authors:  Simon Deycmar; Erica Faccin; Tamara Kazimova; Philip A Knobel; Irma Telarovic; Fabienne Tschanz; Verena Waller; Rona Winkler; Carmen Yong; Dario Zingariello; Martin Pruschy
Journal:  Br J Radiol       Date:  2019-11-11       Impact factor: 3.039

3.  Proton therapy for newly diagnosed pediatric diffuse intrinsic pontine glioma.

Authors:  Ai Muroi; Masashi Mizumoto; Eiichi Ishikawa; Satoshi Ihara; Hiroko Fukushima; Takao Tsurubuchi; Hideyuki Sakurai; Akira Matsumura
Journal:  Childs Nerv Syst       Date:  2019-11-14       Impact factor: 1.475

4.  Photon or Proton Therapy for Adolescent and Young Adult Tumors Focused on Long-Term Survivors.

Authors:  Masashi Mizumoto; Yoshiko Oshiro; Kayoko Tsujino; Shosei Shimizu; Takashi Iizumi; Haruko Numajiri; Kei Nakai; Toshiyuki Okumura; Toshinori Soejima; Hideyuki Sakurai
Journal:  Cureus       Date:  2021-04-22

5.  Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.

Authors:  R Borrill; E Cheesman; S Stivaros; I D Kamaly-Asl; K Gnanalingham; John-Paul Kilday
Journal:  Childs Nerv Syst       Date:  2018-08-01       Impact factor: 1.475

6.  Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi-institutional study in Japan.

Authors:  Masashi Mizumoto; Shigeyuki Murayama; Tetsuo Akimoto; Yusuke Demizu; Takashi Fukushima; Yuji Ishida; Yoshiko Oshiro; Haruko Numajiri; Hiroshi Fuji; Toshiyuki Okumura; Hiroki Shirato; Hideyuki Sakurai
Journal:  Cancer Med       Date:  2018-03-31       Impact factor: 4.452

Review 7.  Precision Medicine in Pediatric Neurooncology: A Review.

Authors:  Aaron Y Mochizuki; Isaura M Frost; Melina B Mastrodimos; Ashley S Plant; Anthony C Wang; Theodore B Moore; Robert M Prins; Paul S Weiss; Steven J Jonas
Journal:  ACS Chem Neurosci       Date:  2017-12-27       Impact factor: 4.418

8.  Bragg Peak Localization with Piezoelectric Sensors for Proton Therapy Treatment.

Authors:  Jorge Otero; Ivan Felis; Alicia Herrero; José A Merchán; Miguel Ardid
Journal:  Sensors (Basel)       Date:  2020-05-25       Impact factor: 3.576

Review 9.  Proton versus Photon Radiotherapy for Pediatric Central Nervous System Malignancies: A Systematic Review and Meta-Analysis of Dosimetric Comparison Studies.

Authors:  Roberta Carbonara; Alessia Di Rito; Angela Monti; Giuseppe Rubini; Angela Sardaro
Journal:  J Oncol       Date:  2019-11-27       Impact factor: 4.375

Review 10.  Immunomodulatory Effects of Radiotherapy.

Authors:  Sharda Kumari; Shibani Mukherjee; Debapriya Sinha; Salim Abdisalaam; Sunil Krishnan; Aroumougame Asaithamby
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.